An analysis of all US Food and Drug Administration (FDA) approvals of 45 immune checkpoint inhibitors across 15 tumor types found that PD-L1 was predictive in only 28.9% of cases, and was either not predictive (53.3%) or not tested (17.8%) in the remaining cases (Davis & Patel, 2019). Here, CD274 is linked to neoplasm.